UCLH NHS Foundation Trust and University College London have a close academic and clincal partnership. In the field of immunotherapy, this partnership has led to UCL being ranked second in the world and top in Europe for the number of inventions and patent applications made in relation to CAR T-cells. In 2018, more CAR T-cells were administered at UCLH than in the rest of Europe combined.
To help explore these developments we asked Leigh Wood, the Cell Therapy Team Lead from the Cancer Clinical Trials Unit at UCLH to join us. The discussion covers practical considerations about caring for patients on clinical trials, and explanations of research concepts like Phase I, II and III. Randomised control trials, blinding and placebos; when they are appropriate to use in research, and when they are not.
https://www.ncbi.nlm.nih.gov/pubmed/30940940
https://www.nih.gov/health-information/nih-clinical-research-trials-you/basics
https://www.uclh.nhs.uk/OurServices/ServiceA-Z/Cancer/CCTrials/Pages/Home.aspx
